Dr. Stambler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
275 Collier Rd NW
Ste 500
Atlanta, GA 30309Phone+1 216-844-8500Fax+1 404-351-5983
Education & Training
- Beth Israel Deaconess Medical CenterFellowship, Cardiovascular Disease, 1987 - 1990
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1984 - 1987
- Duke University School of MedicineClass of 1984
Certifications & Licensure
- GA State Medical License 2014 - 2026
- OH State Medical License 1998 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Clinical Cardiac Electrophysiology
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation Start of enrollment: 2019 Apr 24
Publications & Presentations
PubMed
- 310 citationsEfficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or FibrillationBruce S. Stambler, Mark A. Wood, Kenneth A. Ellenbogen, Kimberly T. Perry, Linda K. Wakefield
Circulation. 1996-10-01 - 251 citationsEfficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response studyKenneth A. Ellenbogen, Bruce S. Stambler, Mark A. Wood, Philip T. Sager, Robert C. Wesley
Journal of the American College of Cardiology. 1996-07-01 - 147 citationsRight ventricular outflow versus apical pacing in pacemaker patients with congestive heart failure and atrial fibrillation.Bruce S. Stambler, Kenneth A. Ellenbogen, Xiaozheng Zhang, Thomas R. Porter, Feng Xie
Journal of Cardiovascular Electrophysiology. 2003-11-01
Authored Content
- Nasal Spray Shows Potential for Quickly Treating ArrhythmiaJuly 2018
Press Mentions
- Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022October 25th, 2022
- Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular TachycardiaOctober 17th, 2022
- Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate UpdateAugust 10th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: